|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
RU2321630C2
(ru)
|
2001-08-03 |
2008-04-10 |
Гликарт Биотекнолоджи АГ |
Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
|
|
BRPI0607315B1
(pt)
|
2005-02-07 |
2022-05-17 |
Roche Glycart Ag |
Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
|
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
CA2687819A1
(en)
|
2007-06-06 |
2008-12-11 |
F.Hoffmann-La Roche Ag |
Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
BRPI0919382A2
(pt)
*
|
2008-09-26 |
2016-01-05 |
Roche Glycart Ag |
anticorpos bi-específicos anti-egfr/anti-igf-1r
|
|
CA2754646A1
(en)
|
2009-03-31 |
2010-10-07 |
Roche Glycart Ag |
Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
|
|
US20100247484A1
(en)
*
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
|
KR20110126748A
(ko)
*
|
2009-04-07 |
2011-11-23 |
로슈 글리카트 아게 |
이중특이적 항-ｅｒｂｂ-1/항-ｃ-ｍｅｔ 항체
|
|
CN102369214B
(zh)
|
2009-04-07 |
2019-04-12 |
罗氏格黎卡特股份公司 |
三价、双特异性抗体
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
AU2010338305A1
(en)
*
|
2009-12-29 |
2012-05-24 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
KR20130005264A
(ko)
*
|
2010-01-11 |
2013-01-15 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항-ｃｄ200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들
|
|
US20110200595A1
(en)
*
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
|
AR080793A1
(es)
*
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
CN101875697B
(zh)
*
|
2010-04-15 |
2014-04-30 |
北京天广实生物技术股份有限公司 |
新型抗egfr人源抗体tgm10的设计及其应用
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
CN102153647B
(zh)
*
|
2011-01-27 |
2012-07-04 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗egfr人源化抗体l3-h3及其编码基因与应用
|
|
EP2672999A2
(en)
|
2011-02-10 |
2013-12-18 |
Roche Glycart AG |
Improved immunotherapy
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
JPWO2012121167A1
(ja)
|
2011-03-04 |
2014-07-17 |
日本電気株式会社 |
個体識別システム、個体識別方法及びそれらに用いられる装置、プログラム
|
|
HRP20181355T1
(hr)
|
2011-08-23 |
2018-10-19 |
Roche Glycart Ag |
Bispecifične molekule koje se vežu na antigen
|
|
CN107586340B
(zh)
|
2011-08-23 |
2022-01-21 |
罗切格利卡特公司 |
对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
|
|
PH12013502531A1
(en)
|
2011-08-23 |
2014-01-20 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
MX2014002289A
(es)
|
2011-08-26 |
2015-03-20 |
Merrimack Pharmaceuticals Inc |
Anticuerpos fc especificos en tandem.
|
|
BR112014006537A2
(pt)
|
2011-09-23 |
2017-11-28 |
Roche Glycart Ag |
anticorpos biespecíficos, formulação farmacêutica, usos de um anticorpo biespecífico, método de tratamento, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo biespecífico
|
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
|
KR20140130455A
(ko)
|
2012-03-02 |
2014-11-10 |
로슈 글리카트 아게 |
Adcc-강화 항체를 사용한 암 치료용 예측 바이오마커
|
|
ES2694679T3
(es)
*
|
2012-03-27 |
2018-12-26 |
Green Cross Corporation |
Epitopos de antígeno de superficie receptor de factor de crecimiento epidérmico y uso de los mismos
|
|
WO2013173255A2
(en)
*
|
2012-05-17 |
2013-11-21 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind egfr
|
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
|
RU2015100656A
(ru)
|
2012-06-27 |
2016-08-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
|
|
CN104662045B
(zh)
|
2012-08-07 |
2019-04-05 |
罗切格利卡特公司 |
包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
|
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
|
US9180185B2
(en)
*
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
|
CN110845618A
(zh)
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
UA119320C2
(uk)
|
2013-02-26 |
2019-06-10 |
Рош Глікарт Аг |
Активуюча т-клітини біспецифічна антигензв'язувальна молекула
|
|
MX2015011712A
(es)
|
2013-03-06 |
2016-04-04 |
Merrimack Pharmaceuticals Inc |
Anticerpos biespecificos fc en fila anti-c-met.
|
|
EA201591977A1
(ru)
*
|
2013-04-22 |
2016-06-30 |
Гликотоп Гмбх |
Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
KR20160083949A
(ko)
|
2013-11-13 |
2016-07-12 |
자임워크스 인코포레이티드 |
Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도
|
|
EP3662928A1
(en)
*
|
2014-04-10 |
2020-06-10 |
OBI Pharma Inc. |
Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
|
|
SMT202400235T1
(it)
|
2014-08-04 |
2024-07-09 |
Hoffmann La Roche |
Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
JP6889660B2
(ja)
|
2014-10-23 |
2021-06-18 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
抗ｎｋｇ２ａ剤を用いた癌の処置
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
BR112017010513A2
(pt)
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
EP3356409A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
SG11201808085WA
(en)
|
2016-03-22 |
2018-10-30 |
Hoffmann La Roche |
Protease-activated t cell bispecific molecules
|
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
|
US10753936B2
(en)
|
2016-07-22 |
2020-08-25 |
Van Andel Research Institute |
Method of detecting the level of a glycan
|
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に対する二重特異性抗体
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
MX2019011526A
(es)
|
2017-03-27 |
2019-12-05 |
Hoffmann La Roche |
Receptores de union a antigeno mejorados.
|
|
CA3054104A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptor formats
|
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
AU2018247767B2
(en)
|
2017-04-03 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to STEAP-1
|
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
HUE060019T2
(hu)
|
2017-04-05 |
2023-01-28 |
Hoffmann La Roche |
Anti-LAG3 antitestek
|
|
JP2020516638A
(ja)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
|
|
GB201710836D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
|
CN107881160A
(zh)
*
|
2017-08-11 |
2018-04-06 |
百奥泰生物科技(广州)有限公司 |
一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
|
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
|
EP3728317A2
(en)
|
2017-12-21 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/wt1
|
|
WO2019122046A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Universal reporter cell assay for specificity test of novel antigen binding moieties
|
|
WO2019129677A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Anti-vegf antibodies and methods of use
|
|
CN118772287A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
EP3802624A4
(en)
*
|
2018-06-01 |
2022-03-23 |
Musc Foundation for Research Development |
GLYCAN ANALYSIS OF PROTEINS AND CELLS
|
|
AR117468A1
(es)
|
2018-12-21 |
2021-08-11 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A VEGF Y A IL-1b Y MÉTODOS DE UTILIZACIÓN
|
|
WO2020127618A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
TWI829831B
(zh)
|
2018-12-21 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合cd3之抗體
|
|
JP2022513495A
(ja)
|
2018-12-21 |
2022-02-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
|
|
WO2020136147A1
(en)
|
2018-12-26 |
2020-07-02 |
Innate Pharma |
Compounds and methods for treatment of head and neck cancer
|
|
WO2020260329A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding cea and 4-1bbl
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
US12168690B2
(en)
|
2019-07-26 |
2024-12-17 |
Abl Bio Inc. |
Anti-EGFR/anti-4-1BB bispecific antibody
|
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
SG11202112491WA
(en)
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
CN114423791B
(zh)
|
2019-09-18 |
2026-01-09 |
豪夫迈·罗氏有限公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
|
|
KR20220100963A
(ko)
|
2019-12-18 |
2022-07-18 |
에프. 호프만-라 로슈 아게 |
Hla-a2/mage-a4에 결합하는 항체
|
|
CN111018990A
(zh)
*
|
2020-02-10 |
2020-04-17 |
张喜田 |
一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
|
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
US20230181712A1
(en)
|
2020-05-11 |
2023-06-15 |
Hoffmann-La Roche Inc. |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
EP4161644A2
(en)
|
2020-06-08 |
2023-04-12 |
F. Hoffmann-La Roche AG |
Anti-hbv antibodies and methods of use
|
|
PE20231552A1
(es)
|
2020-06-19 |
2023-10-03 |
Hoffmann La Roche |
Anticuerpos biespecificos para linfocitos t activados por proteasa
|
|
KR20230025665A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
Cd3에 결합하는 항체
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
AU2021291005A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and FolR1
|
|
BR112022025250A2
(pt)
|
2020-06-19 |
2022-12-27 |
Hoffmann La Roche |
Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, métodos para produzir uma molécula e induzir a lise de uma célula, composição farmacêutica, uso da molécula, métodos de tratamento de uma doença e invenção
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
IL297880A
(en)
|
2020-06-23 |
2023-01-01 |
Hoffmann La Roche |
Agonistic cd28 antigen binding molecules targeting her2
|
|
US20220041672A1
(en)
|
2020-06-24 |
2022-02-10 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
CN115916830A
(zh)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
抗cd3/抗cd28双特异性抗原结合分子
|
|
EP4178985A1
(en)
|
2020-07-10 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
|
PE20230998A1
(es)
|
2020-08-03 |
2023-06-26 |
Hoffmann La Roche |
Receptores de union al antigeno mejorada
|
|
CN116648507A
(zh)
|
2020-08-28 |
2023-08-25 |
基因泰克公司 |
宿主细胞蛋白的CRISPR/Cas9多重敲除
|
|
CN116323663A
(zh)
|
2020-09-04 |
2023-06-23 |
豪夫迈·罗氏有限公司 |
与vegf-a和ang2结合的抗体及其使用方法
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
JP2023547447A
(ja)
|
2020-10-28 |
2023-11-10 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
改良型抗原結合受容体
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
EP4277705A1
(en)
|
2021-01-12 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
|
WO2022152701A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック， インコーポレイテッド |
抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
|
|
CN117157312A
(zh)
|
2021-03-30 |
2023-12-01 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的多肽
|
|
WO2022225880A1
(en)
|
2021-04-19 |
2022-10-27 |
Genentech, Inc. |
Modified mammalian cells
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
JP2024530402A
(ja)
|
2021-07-12 |
2024-08-21 |
ジェネンテック， インコーポレイテッド |
抗体－リパーゼ結合を減少させるための構造
|
|
CA3224853A1
(en)
|
2021-07-14 |
2023-01-19 |
Gautham GAMPA |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
AU2022315528A1
(en)
|
2021-07-22 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
JP2024537335A
(ja)
|
2021-10-14 |
2024-10-10 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
新規インターロイキン－７イムノコンジュゲート
|
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
PE20241586A1
(es)
|
2021-11-25 |
2024-08-01 |
Hoffmann La Roche |
Receptores de union al antigeno mejorados
|
|
EP4437006A1
(en)
|
2021-11-26 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
CN116333117B
(zh)
*
|
2021-12-16 |
2024-04-26 |
徕特康(苏州)生物制药有限公司 |
抗表皮生长因子受体抗体及其制备方法和用途
|
|
CN116333116B
(zh)
*
|
2021-12-16 |
2024-03-05 |
徕特康(苏州)生物制药有限公司 |
抗表皮生长因子受体抗体及其制备方法和用途
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
CN118510815A
(zh)
|
2022-02-11 |
2024-08-16 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
CN119095881A
(zh)
|
2022-03-25 |
2024-12-06 |
豪夫迈·罗氏有限公司 |
经改善的嵌合受体
|
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
|
CA3261283A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory Proteins and Associated Methods
|
|
JP2025534285A
(ja)
|
2022-09-29 |
2025-10-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ポリペプチド
|
|
AU2023356326A1
(en)
|
2022-10-06 |
2025-03-27 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
CN120152989A
(zh)
|
2022-11-03 |
2025-06-13 |
豪夫迈·罗氏有限公司 |
抗cd19/抗cd28双特异性抗体的组合疗法
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
CN120187748A
(zh)
|
2022-11-15 |
2025-06-20 |
豪夫迈·罗氏有限公司 |
抗原结合分子
|
|
WO2024114676A1
(zh)
|
2022-11-29 |
2024-06-06 |
江苏恒瑞医药股份有限公司 |
Cldn18.2/4-1bb结合蛋白及其医药用途
|
|
CN119546630A
(zh)
|
2022-12-08 |
2025-02-28 |
南京诺唯赞生物科技股份有限公司 |
特异性结合rsv的抗体
|
|
IL321951A
(en)
|
2023-01-18 |
2025-09-01 |
Genentech Inc |
Multispecific antibodies and their uses
|
|
AU2024209384A1
(en)
|
2023-01-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
JP2026505747A
(ja)
|
2023-01-25 |
2026-02-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｓｆ１ｒおよびｃｄ３に結合する抗体
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
|
WO2024206788A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
WO2024208776A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
Agonistic split antibodies
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
AU2024269754A1
(en)
|
2023-05-08 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
TW202509065A
(zh)
|
2023-05-16 |
2025-03-01 |
瑞士商赫孚孟拉羅股份公司 |
經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
|
|
CN121241068A
(zh)
|
2023-06-01 |
2025-12-30 |
豪夫迈·罗氏有限公司 |
靶向bcma和cd28的双特异性抗体
|
|
AR132805A1
(es)
|
2023-06-01 |
2025-07-30 |
Hoffmann La Roche |
Moléculas de unión al antígeno inmunoestimuladoras que se unen específicamente a bcma
|
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
AU2024299328A1
(en)
|
2023-07-21 |
2026-01-22 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
WO2025099120A1
(en)
|
2023-11-09 |
2025-05-15 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies with conditional activity
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
US20260071002A1
(en)
|
2023-12-20 |
2026-03-12 |
Hoffmann-La Roche Inc. |
Antibodies binding to ceacam5
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2026019692A2
(en)
|
2024-07-15 |
2026-01-22 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory fusion proteins and related methods
|
|
WO2026041568A1
(en)
|
2024-08-20 |
2026-02-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and dotam
|
|
WO2026052654A1
(en)
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|
|
WO2026052652A1
(en)
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|